EVX-V1

July 1, 2026: Evaxion A/S (NASDAQ: EVAX) announced it will present new preclinical data for its cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop (IHW) 2026 in Montreal (July 11–15, 2026). The data will be presented as a poster (abstract: “AI-driven multi-antigen vaccine design to address cytomegalovirus infection, latency, and immune evasion”) on July 12, 2026 (9:30–11:30am ET) by Gry Persson, and is intended to guide final antigen selection for a broadly protective CMV vaccine candidate as the program progresses “according to plan.”

EVX-V1 is described as a next-generation, multi-component CMV vaccine combining AI-discovered novel antigens with AI-optimized versions of established CMV vaccine antigens, including an AI-optimized pre-fusion glycoprotein B (gB) antigen that has shown superior performance versus traditional gB in terms of enhanced CMV neutralization. The release states these novel antigens induce specific immune responses and inhibit viral infection and reduce cell-to-cell spread in cellular and animal models.